Peer-influenced content. Sources you trust. No registration required. This is HCN.

Features:
CME JOBS OUTBREAKS PEER-TO-PEER QUIZZES & QUESTIONS MEDTECH

MedPage TodayASCO Addresses PARP Controversy in Guideline Update

A response to “practice-changing data” in the first- and second-line setting

The American Society of Clinical Oncology (ASCO) has amended its advice against routinely administering PARP inhibitor monotherapy to patients with recurrent platinum-sensitive epithelial ovarian cancer in the second or later-line situation.

Was this Essential useful?

More Essentials From

ACP Internist
Annals of Internal Medicine
British Medical Journal (The BMJ)
Cancer Therapy Advisor
Cleveland Clinic Journal of Medicine
Clinical Advisor
Consultant360
Dana-Farber Cancer Institute
Epoch Health
Healthgrades for Professionals
MDLinx
Neurology Advisor
Oncology Learning Network
Oncology News Central (ONC)
Psych Congress Network
Psychiatrist.com
The New England Journal of Medicine
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form